Izard Nobel LLP Announces Class Action Lawsuit Against Hemispherx Biopharma, Inc.

WEST HARTFORD, CT, Nov 12 (MARKET WIRE) --
The law firm of Izard Nobel LLP, which has significant experience
representing investors in prosecuting claims of securities fraud,
announces that a lawsuit seeking class action status has been filed in
the United States District Court for the Eastern District of Pennsylvania
on behalf of those who purchased the securities of Hemispherx Biopharma,
Inc. ("Hemispherx" or the "Company") (AMEX: HEB) between February 18,
2009 and October 30, 2009 (the "Class Period").

The Complaint charges that defendants violated the federal securities
laws. It is alleged in the Complaint that defendants misled investors
regarding the status of Hemispherx's New Drug Application ("NDA") for its
drug Ampligen with the U.S. Food and Drug Administration ("FDA").
Specifically, defendants failed to disclose that the FDA had requested
several reports from the Company before the NDA could even be considered,
thus delaying the possible approval of Ampligen by several months at a
minimum. Then, on November 2, 2009, when Hemispherx belatedly disclosed
this information, the price of the Company's securities fell 20% to close
at $1.13 on the next trading day, November 3, 2009.

If you are a member of the class, you may, no later than January 11, 2010,
request that the Court appoint you as lead plaintiff of the class. A lead
plaintiff is a class member that acts on behalf of other class members in
directing the litigation. Although your ability to share in any recovery
is not affected by the decision whether or not to seek appointment as a
lead plaintiff, lead plaintiffs make important decisions which could
affect the overall recovery for class members.

While Izard Nobel LLP has not filed a lawsuit against the defendants, to
view a copy of the Complaint initiating the class action or for more
information about the case, and your rights, visit:
www.izardnobel.com/hemispherxbiopharma/, or contact Izard Nobel LLP
toll-free: (800) 797-5499, or by e-mail: firm@izardnobel.com. For more
information about class action cases in general, please visit our website:
www.izardnobel.com.

CONTACT:
Nancy A. Kulesa or Wayne Boulton
(800) 797-5499
www.izardnobel.com
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-